Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise in advanced bladder cancer battle

NCT ID NCT04527991

Disease control Sponsor: Gilead Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called sacituzumab govitecan against standard treatments in 711 people with advanced bladder cancer that had spread or couldn't be removed. The goal was to see if the new drug helped people live longer. Participants received either the new drug or a treatment chosen by their doctor.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

711 people

The number who actually took part.

Started

Jan 2021

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Individuals with histologically documented metastatic or locally advanced unresectable UC defined as * Tumor (T) 4b, any node (N) or * Any T, N 2-3 Tumors of upper and lower urinary tract are permitted. Mixed histologic types are allowed if urothelial is the predominant histology. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1. * Individuals with progression or recurrence following receipt of platinum-containing regimen and anti programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) therapy for metastatic or locally advanced unresectable disease will be enrolled. * Individuals with recurrence or progression ≤12 months following completion of cisplatin-containing chemotherapy given in the neo-adjuvant/adjuvant setting may utilize that line of therapy to be eligible for the study. The 12-month period is counted from completion of surgical intervention or platinum therapy, respectively. These individuals must receive anti PD-1/PD-L1 therapy in the metastatic or locally advanced unresectable setting to be eligible. * Individuals who received either carboplatin or anti PD-1/PD-L1 therapy in the neo- adjuvant/adjuvant setting will not be able to count that line of therapy towards eligibility for the study. * Cisplatin ineligible individuals who meet one of the below criteria and who were treated with carboplatin in the metastatic or locally advanced unresectable settings may count that line of therapy towards eligibility. They must then have received anti PD-1/PD-L1 therapy in metastatic or locally advanced unresectable setting to be eligible for the study. \-- Cisplatin ineligibility is defined as meeting one of the following criteria: * Creatinine Clearance \< 60 mL/min * Grade ≥ 2 Audiometric Hearing Loss * Grade ≥ 2 Peripheral Neuropathy * New York Heart Association (NYHA) Class III heart failure * ECOG PS ≥ 2 * Anti PD-1/PD-L1 therapy administered as part of maintenance therapy may be counted towards eligibility for the study * Individuals who have progressed after receiving enfortumab vedotin in prior lines of therapy, and individuals who are either ineligible or unable to tolerate enfortumab vedotin therapy, are eligible to enroll in the study * Individuals who received only concurrent chemoradiation for bladder preservation without further systemic therapy are not eligible to enroll in the study. The substitution of carboplatin for cisplatin does not constitute a new regimen provided no new chemotherapeutic agents were added to the regimen and no progression was noted prior to the change in platinum. * Individuals with previously treated brain metastases may participate in the study provided they have stable central nervous system disease for at least 4 weeks prior to the first dose of study drug and stabilization of all neurologic symptoms, have no evidence of new or enlarging brain metastases, and are not using steroids \>20 mg of prednisone (or equivalent) daily for brain metastases for at least 7 days prior to first dose of the study drug. * Adequate hematologic counts without transfusion or growth factor support within 2 weeks of study drug initiation (hemoglobin ≥ 9 g/dL, absolute neutrophil count (ANC) ≥1,500/mm\^3, and platelets ≥100,000/µL). * Adequate hepatic function (bilirubin ≤1.5x institutional upper limit of normal (IULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x IULN or ≤ 5 x IULN if known liver metastases and serum albumin \>3 g/dL). Docetaxel will only be option in TPC arm for individuals with a total bilirubin ≤1 x IULN, and an AST and/or ALT ≤1.5x IULN if alkaline phosphatase is also \>2.5 x IULN. * Creatinine clearance ≥30 mL/min as assessed by the Cockcroft-Gault equation or other validated instruments (e.g. Modification of Diet in Renal Disease (MDRD) equation). * Females of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study drug. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. * Females of childbearing potential must be willing to use 2 methods of birth control or be surgically sterile or abstain from heterosexual activity for the course of the study through 6 months after the last dose of study drug. Individuals of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \>2 years. * Males must agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study therapy. Key Exclusion Criteria: * Females who are pregnant or lactating. * Have had a prior anti-cancer monoclonal antibody (mAb)/ antibody-drug conjugate (ADC) within 4 weeks prior to Cycle 1 Day 1 (C1D1) or have had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to C1D1. Individuals participating in observational studies are eligible. * Have received prior chemotherapy for UC with any available standard of care (SOC) therapies in the control arm (i.e., both prior paclitaxel and docetaxel in regions where vinflunine is not an approved therapy, or prior paclitaxel, docetaxel and vinflunine in regions where vinflunine is approved and is commercially available). * Have not recovered (i.e., ≤ Grade 1) from adverse events due to previously administered chemotherapeutic agent. * Note: Individuals with ≤ Grade 2 neuropathy or any grade of alopecia are an exception to this criterion and will qualify for the study. * Note: If Individuals received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study therapy. * Have previously received topoisomerase 1 inhibitors. * Have an active second malignancy. * Note: Individuals with a history of malignancy that have been completely treated and with no evidence of active cancer for 3 years prior to enrollment, or individuals with surgically cured tumors with low risk of recurrence are allowed to enroll in the study after discussion with the medical monitor. * Have active cardiac disease, defined as: * Myocardial infarction or unstable angina pectoris within 6 months of C1D1. * History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication); history of QT interval prolongation. * NYHA Class III or greater congestive heart failure or left ventricular ejection fraction of \<40%. * Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or gastrointestinal (GI) perforation within 6 months of enrollment. * Have an active serious infection requiring anti-infective therapy (Contact medical monitor for clarification). * Have known history of Human Immunodeficiency Virus (HIV)-1/2 with undetectable viral load and on medications that may interfere with SN-38 metabolism. * Have active Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV). In individuals with a history of HBV or HCV, individuals with a detectable viral load will be excluded. * Have other concurrent medical or psychiatric conditions that, in the investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations. * Have inability to tolerate or are allergic to any potential TPC agent or sacituzumab govitecan-hziy or unable or unwilling to receive the doses specified in the protocol. * Have inability to complete all specified study procedures for any reason. Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Locally advanced or metastatic unresectable urothelial cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Locally advanced or metastatic unresectable urothelial cancer

Contacts and locations

Locations

  • 1st Hospital Jilin University

    Changchun, 130021, China

  • 401 General Military Hospital of Athens

    Athens, 115 25, Greece

  • Affiliated Tumor Hospital of Xinjiang Medical University

    Ürümqi, 830000, China

  • Alexandra General Hospital

    Athens, 11528, Greece

  • Anassa General Clinic

    Thessaloniki, 54623, Greece

  • Anhui Provincial Cancer Hospital

    Hefei, 230031, China

  • Asan Medical Center

    Seoul, 05505, South Korea

  • Ashford Cancer Centre Research - ICON Cancer Centre Adelaide

    Kurralta Park, South Australia, 5037, Australia

  • Asklepios Klinik Altona

    Hamburg, 22763, Germany

  • Athens Medical Center

    Marousi, 151 25, Greece

  • Attikon Hospital

    Chaïdári, 124 62, Greece

  • Austin Health

    Heidelberg, Victoria, 3084, Australia

  • Az Maria Middelares Ghent

    Ghent, 9000, Belgium

  • Azienda Ospedaliera Santa Maria di Terni

    Terni, 05100, Italy

  • Azienda Ospedaliera Universitaria Integrata Verona

    Verona, 37126, Italy

  • Azienda Ospedaliero Universitaria Maggiore Della Carita

    Novara, 28100, Italy

  • Azienda Ospedaliero Universitaria Pisana

    Pisa, 56126, Italy

  • Azienda Ospedaliero-Universitaria San Luigi Gonzaga

    Torino, 10043, Italy

  • BRCR Medical Center, Inc

    San Juan, PR, 00907, Puerto Rico

  • Bagcilar Medipol Mega Universite Hastanesi

    Istanbul, 34214, Turkey (Türkiye)

  • Baptist MD Anderson Cancer Center

    Jacksonville, Florida, 32207, United States

  • Barts Health NHS Trust

    London, EC1A 7BE, United Kingdom

  • Beijing Cancer Hospital

    Beijing, 100142, China

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • Bioclinic - Thessaloniki

    Thessaloniki, 546 22, Greece

  • Boca Raton Clinical Research Global USA - Plantation

    Plantation, Florida, 33322, United States

  • British Columbia Cancer Agency-Vancouver Centre

    Vancouver, V5Z 4E6, Canada

  • CHU Saint Andre

    Bordeaux, 33075, France

  • Calvary Mater Newcastle

    Waratah, New South Wales, 2298, Australia

  • Cancer Hospital of the University of Chinese Academy of Sciences Zhejiang Cancer Hospital

    Hangzhou, 310022, China

  • Cebeci Hastanesi

    Mamak, 6620, Turkey (Türkiye)

  • Center for Cancer and Blood Disorders

    Fort Worth, Texas, 76104, United States

  • Centre Antoine Lacassagne

    Nice, 06189, France

  • Centre Eugene Marquis

    Rennes, 35042, France

  • Centre Francois Baclesse

    Caen, 14076, France

  • Centre Georges- Francois Leclerc

    Dijon, 21000, France

  • Centre Hospiltalier Universitaire Brest - Hôpital Morvan

    Brest, 29200, France

  • Centre Hospitalier Departemental Vendee

    La Roche-sur-Yon, 85925 CEDEX 9, France

  • Centre Hospitalier Privé Saint-Grégoire

    Saint-Grégoire, 35760, France

  • Centre Hospitalier Universitaire de Liège

    Liège, B-4000, Belgium

  • Centre Hospitalier Universitaire de Nimes

    Nîmes, 30029, France

  • Centre Jean Perrin

    Clermont-Ferrand, 63011, France

  • Centre Leon Berard

    Lyon, 69373, France

  • Centre Oscar Lambret

    Lille, 59000, France

  • Centro Hospitalar de Leiria - Hospital de Santo André

    Leiria, 2410-197, Portugal

  • Centro Hospitalar de Lisboa Norte - Hospital de Santa Maria

    Lisbon, 1649-035, Portugal

  • Centro Hospitalar de Tras-os-Montes e Alto Douro

    Vila Real, 5000, Portugal

  • Centro di Riferimento Oncologico di Aviano

    Aviano, 33081, Italy

  • Centrum fur Hamatologie und Onkologie Bethanien

    Frankfurt am Main, 60389, Germany

  • Chaim Sheba Medical Center

    Tel Litwinsky, 52621, Israel

  • Chang Gung Memorial Hospital - Linkou Branch

    Taoyuan, 333, Taiwan

  • Charité Universitätsmedizin Berlin - Campus Benjamin Franklin

    Wien, 1100, Germany

  • Chiayi Chang Gung Memorial Hospital

    Buzi, 613, Taiwan

  • China Medical University Hospital

    Taichung, 40447, Taiwan

  • Chinese Academy of Medical Sciences Cancer Hospital

    Beijing, 100730, China

  • Chinese People's Liberation Army General Hospital - 301 Hospital

    Beijing, 100039, China

  • Chongqing University Cancer Hospital

    Chongqing, 400030, China

  • Chris O'Brien Lifehouse

    North Ryde, New South Wales, 2109, Australia

  • Chungbuk National University Hospital

    Cheongju-si, 361-711, South Korea

  • Chungnam National University Hospital

    Daejeon, 35015, South Korea

  • Cleveland Clinic

    Cleveland, Ohio, 44195, United States

  • Clinica Universidad de Navarra

    Pamplona, 31008, Spain

  • Clinical Hospital Centre "Sestre Milosrdnice"

    Zagreb, 10000, Croatia

  • Clinical Hospital Centre Split

    Split, 21000, Croatia

  • Clínica Universidad de Navarra - Madrid

    Madrid, 28027, Spain

  • Complexo Hospitalario de Ourense (CHOU)

    Ourense, 32005, Spain

  • Cross Cancer Institute

    Edmonton, T6G 1Z2, Canada

  • Dorset County Hospital NHS Foundation Trust

    Dorchester, DT1 2JY, United Kingdom

  • East and North Hertfordshire NHS Trust

    Middlesex, HA6 2RN, United Kingdom

  • Evex Medical corporation

    Tbilisi, 0160, Georgia

  • Fakultni nemocnice Olomouc

    Olomouc, 775 20, Czechia

  • Gachon University Gil Medical Center

    Incheon, 405-760, South Korea

  • Grand Hôpital De Charleroi - Notre Dame

    Charleroi, 6000, Belgium

  • Guys and Saint Thomas NHS Foundation Trust, Guy's Hospital

    London, SE1 9RT, United Kingdom

  • Hacettepe Universitesi Tip Fakultesi- Kanser Enstitusu

    Ankara, 6230, Turkey (Türkiye)

  • Hadassah University Hospital Ein Kerem

    Jerusalem, 91120, Israel

  • Harold C. Simmons Comprehensive Cancer Center

    Dallas, Texas, 75390, United States

  • Henry Dunant Hospital

    Athens, 115 26, Greece

  • High Technology Hospital MedCenter

    Batumi, 6000, Georgia

  • Hong Kong United Oncology Centre

    Kowloon, Hong Kong

  • Hospital Clinic de Barcelona

    Barcelona, 8036, Spain

  • Hospital General Universitario Gregorio Maranon

    Madrid, 28007, Spain

  • Hospital Reina Sofia

    Córdoba, 14004, Spain

  • Hospital Sant Joan de Déu de Manresa

    Manresa, 08243, Spain

  • Hospital Universitari Vall D'Hebron

    Barcelona, 08035, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Universitario Marqués de Valdecilla

    Santander, 39008, Spain

  • Hospital Universitario Puerta de Hierro de Majadahonda

    Majadahonda, 28222, Spain

  • Hospital Universitario Ramon y Cajal

    Madrid, 28034, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, 41013, Spain

  • Hospital de Braga

    Braga, 4710-243, Portugal

  • Hospital del Mar - Parc de Salut

    Barcelona, 08003, Spain

  • Hunan Cancer Hospital - Xiangya Hospital - Central South University

    Changsha, 410013, China

  • Hôpital Européen Georges-Pompidou

    Paris, 75015, France

  • Hôpital Foch

    Suresnes, 92150, France

  • Hôpitaux Universitaires de Genève

    Geneva, 1205, Switzerland

  • ICON Cancer Centre Hobart

    Hobart, Tasmania, 7001, Australia

  • Icon Cancer Centre Farrer Park

    Singapore, 217562, Singapore

  • Icon Cancer Centre Wesley

    Auchenflower, Queensland, 4066, Australia

  • Institut Claudius Regaud

    Toulouse, 31059, France

  • Institut Für Versorgungsforschung in Der Onkologie

    Koblenz, 56068, Germany

  • Institut Gustave Roussy

    Villejuif, 94805, France

  • Institut Régional du Cancer de Montpellier ICM Val d' Aurelle

    Montpellier, 34090, France

  • Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E

    Porto, Portugal

  • Interbalkan Medical Center of Thessaloniki

    Thessaloniki, 555 35, Greece

  • Istanbul Acibadem University Maslak Hospital

    Istanbul, 34457, Turkey (Türkiye)

  • Istituto Oncologico Della Svizzera Italiana (IOSI)

    Bellinzona, 6500, Switzerland

  • Istituto Regina Elena

    Roma, 00144, Italy

  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

    Meldola, 47014, Italy

  • Istituto Tumori Bari Giovanni Paolo II - IRCCS

    Bari, 70124, Italy

  • Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia

    Candiolo (TO), 10060, Italy

  • Jerarsi Clinic

    Tbilisi, 0167, Georgia

  • Jewish General Hospital

    Montreal, H3T 1E2, Canada

  • Juravinski Hospital and Cancer Centre

    Hamilton, L8V 5C2, Canada

  • Kaohsiung Chang Gung Memorial Hospital

    Kaohsiung City, 833, Taiwan

  • Kaohsiung Veterans General Hospital

    Kaohsiung City, 813, Taiwan

  • Karolinska Universitetssjukhuset - Solna

    Stockholm, 171 76, Sweden

  • Krankenhaus Der Barmherzigen Bruder Wien

    Vienna, 1020, Austria

  • L. Managadze National Center of Urology

    Tbilisi, 0144, Georgia

  • Les Hôpitaux Universitaires de Strasbourg

    Strasbourg, 67091, France

  • Liaoning Cancer Hospital and Institute

    Shenyang, 110042, China

  • Liverpool Hospital

    Nedlands, Western Australia, 6009, Australia

  • London Health Sciences Centre

    London, N6A 4G5, Canada

  • Länssjukhuset Ryhov

    Jönköping, 553 05, Sweden

  • MD Anderson Cancer Center

    Madrid, 28033, Spain

  • Malteser Waldkrankenhaus Erlangen

    Erlangen, 91054, Germany

  • Mayo Clinic - Arizona

    Phoenix, Arizona, 85054, United States

  • McGill University Health Centre

    Montreal, H4A 3J1, Canada

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia, 20010, United States

  • Medical Park Izmır Hastanesi

    Izmir, 35575, Turkey (Türkiye)

  • Meir Medical Center

    Kfar Saba, 44281, Israel

  • Monash Health

    Clayton, Victoria, 3168, Australia

  • Montefiore Medical Center

    The Bronx, New York, 10467, United States

  • Multiprofile Hospital for Active Treatment Heart and Brain EAD

    Pleven, 5800, Bulgaria

  • NHS Greater Glasgow and Clyde

    Glasgow, G12 0YN, United Kingdom

  • Nanjing Drum Tower Hospital

    Nanjing, 210008, China

  • National Cancer Center

    Goyang-si, 10408, South Korea

  • National Cheng Kung University Hospital

    Tainan, 70403, Taiwan

  • National Taiwan University Hospital

    Taipei, 100, Taiwan

  • National University Hospital

    Singapore, 119074, Singapore

  • New Hospitals

    Tbilisi, 0114, Georgia

  • Oklahoma Cancer Specialists and Research Institute (OCSRI)

    Tulsa, Oklahoma, 74104, United States

  • Ordensklinikum Linz GmbH Barmherzige Schwestern

    Linz, 4010, Austria

  • Ospedale Civile Di Sondrio

    Sondrio, 23100, Italy

  • Ospedale Policlinico San Martino

    Genova, 16132, Italy

  • Ospedale San Donato

    Arezzo, 52100, Italy

  • Ospedale San Raffaele

    Milan, 20132, Italy

  • Ospedale di Trento - Presidio Ospedaliero Santa Chiara

    Trento, 38122, Italy

  • Oxford University Hospitals NHS Foundation Trust

    Oxford, OX3 7LE, United Kingdom

  • Peking University First Hospital

    Beijing, 100034, China

  • Penn State Hershey Cancer Institute

    Hershey, Pennsylvania, 17033, United States

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, 3000, Australia

  • Prince of Wales Hospital

    Hong Kong, 0, Hong Kong

  • Princess Margaret Cancer Centre

    Toronto, M5G 2M9, Canada

  • Pusan National University Hospital

    Busan, 49241, South Korea

  • Pusan National University Yangsan Hospital

    Gyeongsangnam-do, 50612, South Korea

  • Qilu Hospital of Shandong University

    Jinan, 250012, China

  • Queen Mary Hospital

    Hong Kong, Hong Kong

  • R.S. McLaughlin Durham Regional Cancer Centre

    Oshawa, L1G 2B9, Canada

  • Rabin Medical Center

    Petah Tikva, 4941492, Israel

  • Rambam Health Care Campus

    Haifa, 3109601, Israel

  • Ramsay Health Clinic Belharra

    Bayonne, France

  • Regional University General Hospital of Herakleio, Crete

    Herakleio, 81352, Greece

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

  • Royal Preston Hospital

    Preston, PR2 9HT, United Kingdom

  • Samsung Medical Center

    Seoul, 06351, South Korea

  • Sarah Cannon Research Institute London

    London, W1G 6AD, United Kingdom

  • Seattle Cancer Care Alliance (SCCA)

    Seattle, Washington, 98109, United States

  • Seoul National University Bundang Hospital

    Seongnam-si, 13620, South Korea

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, 03722, South Korea

  • Shamir Medical Center (Assaf Harofeh)

    Be’er Ya‘aqov, 7030000, Israel

  • Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital

    Chengdu, 610072, China

  • Sir Charles Gairdner Hospital

    Nedlands, Western Australia, 6009, Australia

  • Southern Adelaide Local Health Network Incorporated

    Bedford Park, South Australia, 5042, Australia

  • Specialized Hospital for Active Treatment of Oncological Diseases - Sofia District

    Sofia, 1233, Bulgaria

  • Studienpraxis Urologie

    Nürtingen, 72622, Germany

  • Summit Cancer Centers

    Spokane, Washington, 99208, United States

  • Sun Yat-Sen University Cancer Center

    Guangzhou, 510060, China

  • Sunshine Hospital

    Saint Albans, Victoria, 3021, Australia

  • Swansea Bay University Health Board

    Port Talbot, SA12 7BR, United Kingdom

  • T.C. Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi

    Istanbul, 34722, Turkey (Türkiye)

  • Taichung Veterans General Hospital

    Taichung, Taiwan 407, Taiwan

  • Taipei Tzu Chi General Hospital

    New Taipei City, 231405, Taiwan

  • Taipei Veterans General Hospital

    Taipei, 11217, Taiwan

  • Tallaght University Hospital

    Dublin, D24 NR0A, Ireland

  • Tan Tock Seng Hospital

    Singapore, 308433, Singapore

  • Tel Aviv Medical Center (Ichilov Hospital)

    Tel Aviv, 6423906, Israel

  • The Catholic University of Korea Saint Vincent's Hospital

    Suwon, 16247, South Korea

  • The Catholic University of Korea Seoul Saint Mary's Hospital

    Seoul, 137-040, South Korea

  • The Christie NHS Foundation Trust

    Manchester, M20 4BX, United Kingdom

  • The First Affiliated Hospital of Fujian Medical University

    Fujian, 350005, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, 330006, China

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, 325000, China

  • The Royal Marsden NHS Foundation Trust

    Surrey, SM2 5PT, United Kingdom

  • The Royal Wolverhampton NHS Trust

    Wolverhampton, WV10 0QP, United Kingdom

  • Theagenio Anticancer Hospital of Thessaloniki

    Thessaloniki, 546 39, Greece

  • Thompson Oncology Group - Knoxville Downtown

    Knoxville, Tennessee, 37916, United States

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, 300060, China

  • Trakya Universitesi Saglik Arastirma ve Uygulama Merkezi

    Edirne, 22030, Turkey (Türkiye)

  • UCLA Hematology/ Oncology

    Los Angeles, California, 90095, United States

  • Unidade Local de Saúde da Guarda - Hospital Sousa Martins

    Guarda, 6300-858, Portugal

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, 430030, China

  • Union Hospital of Fujian Medical University

    Fuzhou, 350001, China

  • Universitaetsspital Zurich - Klinik fur Medizinische Onkologie und Hematologie

    Zurich, 8091, Switzerland

  • Universitair Ziekenhuis Gent

    Ghent, 9000, Belgium

  • Universitair Ziekenhuis Leuven

    Leuven, 3000, Belgium

  • Universitatsklinik Dresden

    Dresden, 01307, Germany

  • Universitatsklinikum Munster

    Münster, 48149, Germany

  • Universitetssjukhuset i Linköping

    Linköping, 581 85, Sweden

  • University Cancer Specialists - Knoxville

    Knoxville, Tennessee, 37920, United States

  • University Hospital Basel

    Basel, 4051, Switzerland

  • University Hospital Centre Zagreb

    Zagreb, Croatia

  • University Hospital Of Ioannina

    Ioannina, 45332, Greece

  • University Hospital Waterford

    Waterford, X91 ER8E, Ireland

  • University Hospital of Larissa

    Larissa, 413 34, Greece

  • University Hospital of Patras

    Pátrai, 26332, Greece

  • University Hospitals Birmingham NHS Foundation Trust

    Birmingham, B15 2WB, United Kingdom

  • University of Bern

    Bern, 3010, Switzerland

  • University of California Irvine (UCIMC)

    Orange, California, 92868, United States

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa, 52242, United States

  • University of Maryland School of Medicine

    Baltimore, Maryland, 21201, United States

  • Università Campus Bio-Medico di Roma

    Rome, 00128, Italy

  • Universitätsklinik für Innere Medizin Graz

    Graz, 8036, Austria

  • Universitätsklinikum Essen

    Essen, 45147, Germany

  • Universitätsklinikum Tübingen

    Tübingen, 72076, Germany

  • Urocentrum Praha

    Prague, 120 00, Czechia

  • VKV Amerikan Hastanesi Department of Oncology

    Şişli, 34365, Turkey (Türkiye)

  • Weill Cornell Medical College

    New York, New York, 10065, United States

  • West China Hospital Sichuan University

    Chengdu, 610041, China

  • Westmead Hospital

    Westmead, New South Wales, 2145, Australia

  • Zhejiang Provincial People's Hospital - Zhaohui

    Hangzhou, 310014, China

  • qeii health sciences centre - VG site

    Halifax, B3H 2Y9, Canada

  • Álvaro Cunqueiro Hospital

    Vigo, 36213, Spain